Entry Collections
Aging and Public Health (44)
Androgen Receptor in Health and Disease (2)
Aquaporin (2)
Asian Religion (3)
Atherosclerosis and Atherosclerotic Diseases (1)
Autophagy and Cancer (5)
Biopharmaceuticals (14)
Chemical Bond (8)
COVID-19 (66)
Depression and treatment (1)
Extraction Techniques in Sample Preparation (15)
Gastrointestinal Disease (36)
Hypertension and Cardiovascular Diseases (28)
MedlinePlus (2146)
Molecules of the Week (9)
Neuronal Degeneration (4)
Nitric Oxide: Physiology, Pharmacology, and Therapeutic Applications (14)
Nuclear Magnetic Resonance (10)
Organic Synthesis (23)
Peptides for Health Benefits (29)
Remote Sensing Data Fusion (20)
Retinal Disease and Metabolism (4)
Skin Pathologies (3)
Society 5.0 (37)
Tight Junction and Its Proteins (2)
Wastewater Treatment (12)
Page Size:
Submitted by: Kimitoshi Nakamura
Dissociated optic nerve fiber layer (DONFL) appearance is characterized by dimpling of the fundus when observed after vitrectomy with the internal limiting membrane (ILM) peeling in macular diseases. However, the cause of DONFL remains largely unknown. Optical coherence tomography (OCT) findings have indicated that the nerve fiber layer (NFL) and ganglion cells are likely to have been damaged in patients with DONFL appearance. Since DONFL appearance occurs at a certain postoperative period, it is unlikely to be retinal damage directly caused by ILM peeling because apoptosis occurs at a certain period after tissue damage and/or injury. However, it may be due to ILM peeling-induced apoptosis in the retinal tissue. Anoikis is a type of apoptosis that occurs in anchorage-dependent cells upon detachment of those cells from the surrounding extracellular matrix (i.e., the loss of cell anchorage). The anoikis-related proteins βA3/A1 crystallin and E-cadherin are reportedly expressed in retinal ganglion cells. 
Submitted by: Federica Piancone
Neurodegenerative diseases are chronic, progressive disorders that occur in the central nervous system (CNS). They are characterized by the loss of neuronal structure and function and are associated with inflammation. Inflammation of the CNS is called neuroinflammation, which has been implicated in most neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Much evidence indicates that these different conditions share a common inflammatory mechanism: the activation of the inflammasome complex in peripheral monocytes and in microglia, with the consequent production of high quantities of the pro-inflammatory cytokines IL-1β and IL-18. Inflammasomes are a group of multimeric signaling complexes that include a sensor Nod-like receptor (NLR) molecule, the adaptor protein ASC, and caspase-1. The NLRP3 inflammasome is currently the best-characterized inflammasome. Multiple signals, which are potentially provided in combination and include endogenous danger signals and pathogens, trigger the formation of an active inflammasome, which, in turn, will stimulate the cleavage and the release of bioactive cytokines including IL-1β and IL-18.
Submitted by: Donald Alcendor
The JC polyomavirus (JCPyV/JCV) is a member of the Polyomaviridae family and is ubiquitious in the general population, infecting 50–80% of individuals globally. The virus remains latent but can reactivate under conditions of immunosuppression and cause life-threatening disease such as progressive multifocal leukoencephalopathy (PML).  PML can be a complication of HIV disease especially in HIV patients who are not receiving anti retroviral therapy. In immunocompetent individuals, PML is rare however, the incidence of PML is increasing due to the widespread use of immune modulating therapies.  JCV induced PML is rare in solid organ transplant patients but there is documented cases that correlate with immunosuppression that is required allograft transplantation. Currently there no curative therapies for PML with high mortality after diagnosis. 
Submitted by: Samo Ribarič
Nanotechnology (NT) enables a new, alternative pathway for development of AD treatment interventions in human. At present, the NT treatments for attenuation of AD memory impairment are at the animal model stage. They are faced with the twin challenges of the nature of AD: a chronic impairment unique to human and the incomplete understanding of AD′s aetiology.